A global, phase 3 clinical trial will investigate a novel drug in the post neoadjuvant setting that researchers hope will be a significant improvement over the current standard of care.
New Approach May Help Predict HER2+ Tumor Response to Treatment
Researchers have identified quantitative features extracted from MRI images of HER2-positive breast tumors and the tumor environment that may provide cues to patients’ likelihood of response to targeted chemotherapy.
These Are the ASCO 2019 Abstracts That Will Make a Difference
What research abstracts presented at this year’s American Society of Clinical Oncology annual meeting will have the biggest potential impact on clinical practice? Cleveland Clinic Cancer Center physicians make their picks.
Adjuvant T-DM1 Superior to Trastuzumab in Patients with HER2+ Early Breast Cancer
A new option proves effective for patients with HER2+ early breast cancer with residual disease after neoadjuvant therapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Breast Cancer Program Launches Tumor Board Webcast Video Series
Cleveland Clinic’s multidisciplinary approach to cancer care is demonstrated in the new Tumor Board webcast video series. The series launches with an HER2-positive breast cancer case.
Unique HER2 Trial Uses New Targeted Drug Therapy
A unique trial will test the combination of two powerful and targeted breast cancer drugs, determining their safety and tolerability in Phase I and the overall response rate in Phase II.